Hepatology International

Article	Citations
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?	184
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study	103
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines	80
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040	79
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	75
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma	66
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial	63
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	52
Current perspectives on the tumor microenvironment in hepatocellular carcinoma	51
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	51
An international multidisciplinary consensus statement on MAFLD and the risk of CVD	50
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort	49
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?	47
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial	46
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	46
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC	45
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)	45
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis	43
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B	42
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial	42
The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention	39
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease	37
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study	37
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	36
SARS-CoV-2 infection and liver involvement	35

Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy	34
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)	34
Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis	33
Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial	33
Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease	31
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure	30
A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes	30
Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection	29
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	29
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	28
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis	28
Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer	27
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	27
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	27
Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China	26
Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice	26
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients	26
Management of primary sclerosing cholangitis and its complications: an algorithmic approach	25
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?	25
The metabolic profiles and body composition of lean metabolic associated fatty liver disease	25
Chronic hepatitis B: the demise of the ‘inactive carrier’ phase	24
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study	24
Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker	24
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	23
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	23
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load	23
Abstract	23
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	22
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19	22
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies	21
Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study	21
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B	21
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection	21
The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	21
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation	20
A prognostic model of acute-on-chronic liver failure based on sarcopenia	20
Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study	20
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma	20
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population	20
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	20
Management of hepatitis B virus reactivation due to treatment of COVID-19	19
Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study	19
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma	19
A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis	19
Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study	19
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis	19
A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion	19
Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis	19
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications	19
Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice	18

Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	18
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients	18
Increased risk of cancer in patients with primary sclerosing cholangitis	18
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease	18
Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study	18
Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study	18
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation	18
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes	17
Identification of blood metabolites linked to the risk of cholelithiasis: a comprehensive Mendelian randomization study	17
Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study	17
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B	17
Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids	17
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy	17
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	16
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease	16
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients	16
Regression of portal hypertension: underlying mechanisms and therapeutic strategies	16
Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure	16
Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial	16
Implications of liver injury in risk-stratification and management of patients with COVID-19	16
Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia	16
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan	16
Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044	16
Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients	16
Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma	16
Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy	15
A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma	15
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	15
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies	15
Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?	15
HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility	15
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF	15
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	14
Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images	14
Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case–control study	14
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	14
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	14
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma	14
Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease	14
Association between metabolically healthy obesity and non-alcoholic fatty liver disease	13
Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding	13
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response	13
Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait	13
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	13
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice	13
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status	13
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study	13
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	13
Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil	13
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis	13
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	12
Effects of serum branched-chain amino acids on nonalcoholic fatty liver disease and subsequent cardiovascular disease	12
Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure	12
Asia–Pacific association for study of liver guidelines on management of ascites in liver disease	12
Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt	12
Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation	12
Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease	12
Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis	12
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	12
Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma	12
Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials	12
Application of machine learning in liver transplantation: a review	12
Integrated genomic analyses of hepatocellular carcinoma	11
Associations between intake of starchy and non-starchy vegetables and risk of hepatic steatosis and fibrosis	11
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation	11
Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study	11
Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis	11
Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study	11
Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank	11
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan	11
A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients	11
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	11
Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States	11
Establishment of a murine model of acute-on-chronic liver failure with multi-organ dysfunction	11
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	11
Artificial intelligence CT radiomics to predict early recurrence of intrahepatic cholangiocarcinoma: a multicenter study	11
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	11
Consensus on the secondary prevention of primary liver cancer	11
Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors	10
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	10

Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab	10
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial	10
Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma	10
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	10
Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study	10
Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion	10
Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection	10
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	10
Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial	10